ADMA - ADMA Corp Sales Growth YoY (TTM)

This TTM annual sales growth chart demonstrates the pricing power of ADMA Biologics (ADMA), driven by its control over the entire supply chain of critical immunoglobulins. The 6.10 mark characterizes this parameter, confirming revenue stability due to patients' lifelong dependence on the therapy. Meanwhile, the company is optimizing logistics by reducing reliance on external contractors and localizing plasma collection.
ADMA Biologics, Inc. - analytical breakdowns and key metrics (ADMA)

The metric is calculated as the percentage change in revenue over the last twelve months relative to the same period last year. This methodology neutralizes seasonal fluctuations, allowing for an assessment of the business's actual operational resilience during crisis phases. For ADMA Biologics (ADMA), with its unique patents and proprietary plasma collection, this growth confirms the effectiveness of scaling high-margin products. By analyzing the annual revenue dynamics via the TTM metric, an investor determines the stability of cash inflows.